Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J’s Cypher gets heart attack label in EU

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson/Cordis gains CE mark Aug. 27 allowing the firm to promote its Cypher Select Plus sirolimus-eluting stent in Europe as a treatment for acute myocardial infarction. The clearance is based primarily on data from the 712-patient TYPHOON trial that showed Cypher to have a statistically significant advantage over bare-metal stents (7.3% v. 14.3%) for heart attack patients in a composite target vessel failure endpoint measure. Even after the TYPHOON data was published in the New England Journal of Medicine in 2006, however, cardiologists remained cautious about use of drug-eluting stents as a primary AMI treatment, noting the challenge of assessing during an emergent procedure whether the patient is likely to comply with a long-term anti-clotting medication regime that may be necessary to prevent a late stent thrombosis event (1"The Gray Sheet" Sept. 18, 2006, p. 8). Cordis has no plans to bring Cypher Select Plus to the U.S., where AMI remains an off-label indication
Advertisement

Related Content

In An Emergency, Value Of Drug-Eluting Stents Still Questionable, Docs Say
In An Emergency, Value Of Drug-Eluting Stents Still Questionable, Docs Say
Advertisement
UsernamePublicRestriction

Register

MT026515

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel